US panel to weigh continued sale of propoxyphene
This article was originally published in Scrip
Executive Summary
The USFDA's anaesthetic and life support drugs and drug safety/risk management advisory panels will meet on January 30th to consider whether propoxyphene-containing products (such as Xanodyne's Darvocet, Darvon and generics) should remain on the market. The committees will discuss the safety and efficacy data for all products containing the analgesic ingredient, including combination drugs, and whether regulatory action is appropriate. In 2006 the US consumer group Public Citizen petitioned the FDA to begin a phased withdrawal of propoxyphene-containing medicines owing to safety issues. The drug has a cardiotoxic metabolite and has been associated with more than 2,000 accidental deaths in the US since 1981, the group said. Last year Public Citizen sued the FDA for failing to act on the petition.
You may also be interested in...
Rare Diseases: CBER Looks To ‘Lean Into’ Accelerated Approval, Align More With CDER
US FDA biologics center officials spoke about their efforts to increase collaboration and harmonization with the drugs center, and to internally involve more review disciplines in evaluating biomarker evidence, during a Reagan-Udall Foundation meeting that weighed potential use of accelerated approval for neuronopathic mucopolysaccharidoses disorders.
RWE: Non-Interventional Studies Must Be Able To Distinguish A True Treatment Effect, US FDA Says
Agency describes a host of issues sponsors should consider and address before pursuing observational or case-control studies to support regulatory decision-making on drug efficacy or safety; new draft guidance was issued under the FDA’s Real-World Evidence program.
Eye On ODAC: Former Members, FDA’s Pazdur Talk Pre-Meeting Mindsets, Impact Of Sponsor’s Experts
Oncologic Drugs Advisory Committee reps and the Oncology Center of Excellence director go behind the scenes to discuss FDA interactions with panelists, how opinions can change during a meeting, and why the voting question is important.